RxDoctor Payments Data

Heather Snyder, PA

Medical · Colonial Heights, VANPI 1891217055

Payments from drug & device makers

$1,812in general payments, 2019–2025

Across 63 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$281
  • Amgen$198
  • Boston Scientific$192
  • Edwards Lifesciences$169
  • Impulse Dynamics (USA) Inc.$141
  • Kestra Medical Technology Services, Inc.$136
  • plus $695 from 14 others

What the payments were for

  • Food & beverage$1,812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,812 in reported general payments places this provider in the 70th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$43,358
Medicare patients
240
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$176,452
EntrestoSacubitril/Valsartan68$74,647
XareltoRivaroxaban14$18,355
Repatha PushtronexEvolocumab16$13,113
JardianceEmpagliflozin11$12,657
Metoprolol Succinate130$1,232
Atorvastatin Calcium61$769
Rosuvastatin Calcium72$720
Flecainide Acetate20$692
Carvedilol79$587
Valsartan30$557
Potassium Chloride11$535
ClopidogrelClopidogrel Bisulfate39$520
SotalolSotalol Hcl23$423
Losartan Potassium38$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$176,452170 claims
NovartisEntresto$281$74,64768 claims
Johnson & JohnsonXarelto$117$18,35514 claims
Boehringer IngelheimJardiance$82$12,65711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 632 medical providers in Virginia.

Other medical in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →